Listed

Dogwood Therapeutics, Inc.

DWTXNasdaqCIK 1818844HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Operating income−$14.1m, Q2 FY2026
Net income−$11.5m, Q2 FY2026
Dogwood Therapeutics, Inc., income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Research and development$m0.4Research and development, Q3 FY2023, three months to 2023-09-30$374.2k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-08, accession 0001558370-24-014957.Report this figure0.3Research and development, Q4 FY2023, three months to 2023-12-31$298.3k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2025-03-31, accession 0001558370-25-004167. Derived: 12-month figure less the 9-month figure.Report this figure0.3Research and development, Q1 FY2024, three months to 2024-03-31$343.7k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-09, accession 0001558370-25-007109.Report this figure0.3Research and development, Q2 FY2024, three months to 2024-06-30$336.1k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-13, accession 0001558370-25-011319.Report this figure0.5Research and development, Q3 FY2024, three months to 2024-09-30$535.2k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-07, accession 0001104659-25-108169.Report this figure2.3Research and development, Q4 FY2024, three months to 2024-12-31$2.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-18, accession 0001104659-26-031061. Derived: 12-month figure less the 9-month figure.Report this figure2.4Research and development, Q1 FY2025, three months to 2025-03-31$2.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-15, accession 0001104659-26-061938.Report this figure2.6Research and development, Q2 FY2025, three months to 2025-06-30$2.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-14, accession 0001104659-26-096719.Report this figure14.5Research and development, Q3 FY2025, three months to 2025-09-30$14.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-07, accession 0001104659-25-108169.Report this figure2.3Research and development, Q4 FY2025, three months to 2025-12-31$2.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-18, accession 0001104659-26-031061. Derived: 12-month figure less the 9-month figure.Report this figure2.7Research and development, Q1 FY2026, three months to 2026-03-31$2.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-15, accession 0001104659-26-061938.Report this figure3.2Research and development, Q2 FY2026, three months to 2026-06-30$3.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-14, accession 0001104659-26-096719.Report this figure
Operating income$m(1.3)Operating income, Q3 FY2023, three months to 2023-09-30−$1.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-08, accession 0001558370-24-014957.Report this figure(1.1)Operating income, Q4 FY2023, three months to 2023-12-31−$1.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-31, accession 0001558370-25-004167. Derived: 12-month figure less the 9-month figure.Report this figure(1.3)Operating income, Q1 FY2024, three months to 2024-03-31−$1.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-09, accession 0001558370-25-007109.Report this figure(1.1)Operating income, Q2 FY2024, three months to 2024-06-30−$1.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-13, accession 0001558370-25-011319.Report this figure(2.3)Operating income, Q3 FY2024, three months to 2024-09-30−$2.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-07, accession 0001104659-25-108169.Report this figure(7.5)Operating income, Q4 FY2024, three months to 2024-12-31−$7.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-18, accession 0001104659-26-031061. Derived: 12-month figure less the 9-month figure.Report this figure(4.4)Operating income, Q1 FY2025, three months to 2025-03-31−$4.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-15, accession 0001104659-26-061938.Report this figure(3.9)Operating income, Q2 FY2025, three months to 2025-06-30−$3.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-14, accession 0001104659-26-096719.Report this figure(15.8)Operating income, Q3 FY2025, three months to 2025-09-30−$15.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-07, accession 0001104659-25-108169.Report this figure(3.8)Operating income, Q4 FY2025, three months to 2025-12-31−$3.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-18, accession 0001104659-26-031061. Derived: 12-month figure less the 9-month figure.Report this figure(5.1)Operating income, Q1 FY2026, three months to 2026-03-31−$5.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-15, accession 0001104659-26-061938.Report this figure(14.1)Operating income, Q2 FY2026, three months to 2026-06-30−$14.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-14, accession 0001104659-26-096719.Report this figure
Net income$m(1.2)Net income, Q3 FY2023, three months to 2023-09-30−$1.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-08, accession 0001558370-24-014957.Report this figure(1.1)Net income, Q4 FY2023, three months to 2023-12-31−$1.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-31, accession 0001558370-25-004167. Derived: 12-month figure less the 9-month figure.Report this figure(1.3)Net income, Q1 FY2024, three months to 2024-03-31−$1.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-07, accession 0001104659-25-108169.Report this figure(1.0)Net income, Q2 FY2024, three months to 2024-06-30−$1.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-07, accession 0001104659-25-108169.Report this figure(2.3)Net income, Q3 FY2024, three months to 2024-09-30−$2.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-07, accession 0001104659-25-108169.Report this figure(7.7)Net income, Q4 FY2024, three months to 2024-12-31−$7.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-18, accession 0001104659-26-031061. Derived: 12-month figure less the 9-month figure.Report this figure(10.9)Net income, Q1 FY2025, three months to 2025-03-31−$10.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001104659-26-096719.Report this figure(3.8)Net income, Q2 FY2025, three months to 2025-06-30−$3.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001104659-26-096719.Report this figure(15.7)Net income, Q3 FY2025, three months to 2025-09-30−$15.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-07, accession 0001104659-25-108169.Report this figure(3.8)Net income, Q4 FY2025, three months to 2025-12-31−$3.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-18, accession 0001104659-26-031061. Derived: 12-month figure less the 9-month figure.Report this figure(5.0)Net income, Q1 FY2026, three months to 2026-03-31−$5.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001104659-26-096719.Report this figure(11.5)Net income, Q2 FY2026, three months to 2026-06-30−$11.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001104659-26-096719.Report this figure
Diluted EPS$ per share(1.62)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$1.62 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-08, accession 0001558370-24-014957.Report this figurenot reported(1.68)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$1.68 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-09, accession 0001558370-25-007109.Report this figure(1.15)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$1.15 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-13, accession 0001558370-25-011319.Report this figure(2.05)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$2.05 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-07, accession 0001104659-25-108169.Report this figurenot reported(8.45)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$8.45 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-15, accession 0001104659-26-061938.Report this figure(1.99)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$1.99 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-14, accession 0001104659-26-096719.Report this figure(8.20)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$8.20 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-07, accession 0001104659-25-108169.Report this figurenot reported(0.15)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.15 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-15, accession 0001104659-26-061938.Report this figure(0.34)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.34 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-14, accession 0001104659-26-096719.Report this figure
Basic EPS$ per share(1.62)Basic EPS, Q3 FY2023, three months to 2023-09-30−$1.62 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-08, accession 0001558370-24-014957.Report this figurenot reported(1.68)Basic EPS, Q1 FY2024, three months to 2024-03-31−$1.68 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-09, accession 0001558370-25-007109.Report this figure(1.15)Basic EPS, Q2 FY2024, three months to 2024-06-30−$1.15 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-13, accession 0001558370-25-011319.Report this figure(2.05)Basic EPS, Q3 FY2024, three months to 2024-09-30−$2.05 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-07, accession 0001104659-25-108169.Report this figurenot reported(8.45)Basic EPS, Q1 FY2025, three months to 2025-03-31−$8.45 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-15, accession 0001104659-26-061938.Report this figure(1.99)Basic EPS, Q2 FY2025, three months to 2025-06-30−$1.99 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-14, accession 0001104659-26-096719.Report this figure(8.20)Basic EPS, Q3 FY2025, three months to 2025-09-30−$8.20 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-07, accession 0001104659-25-108169.Report this figurenot reported(0.15)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.15 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-15, accession 0001104659-26-061938.Report this figure(0.34)Basic EPS, Q2 FY2026, three months to 2026-06-30−$0.34 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-14, accession 0001104659-26-096719.Report this figure

Balance sheet

Cash and equivalents$9.6m, Q2 FY2026
Shareholders' equity$68.4m, Q2 FY2026
Dogwood Therapeutics, Inc., balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m4.8Cash and equivalents, Q3 FY2023, at 2023-09-30$4.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2023-11-13, accession 0001558370-23-018708.Report this figure3.3Cash and equivalents, FY2023, at 2023-12-31$3.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-03-31, accession 0001558370-25-004167.Report this figure2.4Cash and equivalents, Q1 FY2024, at 2024-03-31$2.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-05-10, accession 0001558370-24-007713.Report this figure3.0Cash and equivalents, Q2 FY2024, at 2024-06-30$3.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-08-09, accession 0001558370-24-011686.Report this figure2.0Cash and equivalents, Q3 FY2024, at 2024-09-30$2.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-08, accession 0001558370-24-014957.Report this figure14.8Cash and equivalents, FY2024, at 2024-12-31$14.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-03-18, accession 0001104659-26-031061.Report this figure17.5Cash and equivalents, Q1 FY2025, at 2025-03-31$17.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-09, accession 0001558370-25-007109.Report this figure13.4Cash and equivalents, Q2 FY2025, at 2025-06-30$13.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-13, accession 0001558370-25-011319.Report this figure10.1Cash and equivalents, Q3 FY2025, at 2025-09-30$10.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-07, accession 0001104659-25-108169.Report this figure6.5Cash and equivalents, FY2025, at 2025-12-31$6.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-14, accession 0001104659-26-096719.Report this figure13.2Cash and equivalents, Q1 FY2026, at 2026-03-31$13.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-15, accession 0001104659-26-061938.Report this figure9.6Cash and equivalents, Q2 FY2026, at 2026-06-30$9.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-14, accession 0001104659-26-096719.Report this figure
Current assets$m5.2Current assets, Q3 FY2023, at 2023-09-30$5.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-13, accession 0001558370-23-018708.Report this figure4.2Current assets, FY2023, at 2023-12-31$4.2m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-03-31, accession 0001558370-25-004167.Report this figure3.2Current assets, Q1 FY2024, at 2024-03-31$3.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-10, accession 0001558370-24-007713.Report this figure3.6Current assets, Q2 FY2024, at 2024-06-30$3.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-09, accession 0001558370-24-011686.Report this figure2.3Current assets, Q3 FY2024, at 2024-09-30$2.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-08, accession 0001558370-24-014957.Report this figure16.5Current assets, FY2024, at 2024-12-31$16.5m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-03-18, accession 0001104659-26-031061.Report this figure19.2Current assets, Q1 FY2025, at 2025-03-31$19.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-09, accession 0001558370-25-007109.Report this figure14.7Current assets, Q2 FY2025, at 2025-06-30$14.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-13, accession 0001558370-25-011319.Report this figure11.7Current assets, Q3 FY2025, at 2025-09-30$11.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-07, accession 0001104659-25-108169.Report this figure8.4Current assets, FY2025, at 2025-12-31$8.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-14, accession 0001104659-26-096719.Report this figure15.0Current assets, Q1 FY2026, at 2026-03-31$15.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-15, accession 0001104659-26-061938.Report this figure11.0Current assets, Q2 FY2026, at 2026-06-30$11.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-14, accession 0001104659-26-096719.Report this figure
Total assets$m5.2Total assets, Q3 FY2023, at 2023-09-30$5.2m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-13, accession 0001558370-23-018708.Report this figure4.2Total assets, FY2023, at 2023-12-31$4.2m. XBRL concept us-gaap:Assets. 10-K filed 2025-03-31, accession 0001558370-25-004167.Report this figure3.2Total assets, Q1 FY2024, at 2024-03-31$3.2m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-10, accession 0001558370-24-007713.Report this figure3.6Total assets, Q2 FY2024, at 2024-06-30$3.6m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-09, accession 0001558370-24-011686.Report this figure2.3Total assets, Q3 FY2024, at 2024-09-30$2.3m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-08, accession 0001558370-24-014957.Report this figure94.3Total assets, FY2024, at 2024-12-31$94.3m. XBRL concept us-gaap:Assets. 10-K filed 2026-03-18, accession 0001104659-26-031061.Report this figure97.0Total assets, Q1 FY2025, at 2025-03-31$97.0m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-09, accession 0001558370-25-007109.Report this figure96.7Total assets, Q2 FY2025, at 2025-06-30$96.7m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-13, accession 0001558370-25-011319.Report this figure92.0Total assets, Q3 FY2025, at 2025-09-30$92.0m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-07, accession 0001104659-25-108169.Report this figure90.2Total assets, FY2025, at 2025-12-31$90.2m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-14, accession 0001104659-26-096719.Report this figure95.2Total assets, Q1 FY2026, at 2026-03-31$95.2m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-15, accession 0001104659-26-061938.Report this figure80.5Total assets, Q2 FY2026, at 2026-06-30$80.5m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-14, accession 0001104659-26-096719.Report this figure
Current liabilities$m0.5Current liabilities, Q3 FY2023, at 2023-09-30$487.1k. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-13, accession 0001558370-23-018708.Report this figure0.4Current liabilities, FY2023, at 2023-12-31$358.5k. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-03-31, accession 0001558370-25-004167.Report this figure0.6Current liabilities, Q1 FY2024, at 2024-03-31$570.1k. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-10, accession 0001558370-24-007713.Report this figure0.5Current liabilities, Q2 FY2024, at 2024-06-30$500.1k. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-09, accession 0001558370-24-011686.Report this figure1.3Current liabilities, Q3 FY2024, at 2024-09-30$1.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-08, accession 0001558370-24-014957.Report this figure3.2Current liabilities, FY2024, at 2024-12-31$3.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-03-18, accession 0001104659-26-031061.Report this figure2.6Current liabilities, Q1 FY2025, at 2025-03-31$2.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-09, accession 0001558370-25-007109.Report this figure1.9Current liabilities, Q2 FY2025, at 2025-06-30$1.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-13, accession 0001558370-25-011319.Report this figure2.6Current liabilities, Q3 FY2025, at 2025-09-30$2.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-07, accession 0001104659-25-108169.Report this figure3.1Current liabilities, FY2025, at 2025-12-31$3.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-14, accession 0001104659-26-096719.Report this figure2.6Current liabilities, Q1 FY2026, at 2026-03-31$2.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-15, accession 0001104659-26-061938.Report this figure2.8Current liabilities, Q2 FY2026, at 2026-06-30$2.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-14, accession 0001104659-26-096719.Report this figure
Total liabilities$m0.5Total liabilities, Q3 FY2023, at 2023-09-30$487.1k. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-13, accession 0001558370-23-018708.Report this figure0.4Total liabilities, FY2023, at 2023-12-31$358.5k. XBRL concept us-gaap:Liabilities. 10-K filed 2025-03-31, accession 0001558370-25-004167.Report this figure0.6Total liabilities, Q1 FY2024, at 2024-03-31$570.1k. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-10, accession 0001558370-24-007713.Report this figure0.5Total liabilities, Q2 FY2024, at 2024-06-30$500.1k. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-09, accession 0001558370-24-011686.Report this figure1.3Total liabilities, Q3 FY2024, at 2024-09-30$1.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-08, accession 0001558370-24-014957.Report this figure30.0Total liabilities, FY2024, at 2024-12-31$30.0m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-03-18, accession 0001104659-26-031061.Report this figure14.2Total liabilities, Q1 FY2025, at 2025-03-31$14.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-09, accession 0001558370-25-007109.Report this figure14.2Total liabilities, Q2 FY2025, at 2025-06-30$14.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-13, accession 0001558370-25-011319.Report this figure14.6Total liabilities, Q3 FY2025, at 2025-09-30$14.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-07, accession 0001104659-25-108169.Report this figure15.3Total liabilities, FY2025, at 2025-12-31$15.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-14, accession 0001104659-26-096719.Report this figure14.6Total liabilities, Q1 FY2026, at 2026-03-31$14.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-15, accession 0001104659-26-061938.Report this figure12.1Total liabilities, Q2 FY2026, at 2026-06-30$12.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-14, accession 0001104659-26-096719.Report this figure
Shareholders' equity$m4.8Shareholders' equity, Q3 FY2023, at 2023-09-30$4.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-08, accession 0001558370-24-014957.Report this figure3.8Shareholders' equity, FY2023, at 2023-12-31$3.8m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-03-18, accession 0001104659-26-031061.Report this figure2.7Shareholders' equity, Q1 FY2024, at 2024-03-31$2.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-07, accession 0001104659-25-108169.Report this figure3.1Shareholders' equity, Q2 FY2024, at 2024-06-30$3.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-07, accession 0001104659-25-108169.Report this figure0.9Shareholders' equity, Q3 FY2024, at 2024-09-30$949.4k. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-07, accession 0001104659-25-108169.Report this figure(10.1)Shareholders' equity, FY2024, at 2024-12-31−$10.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001104659-26-096719.Report this figure7.1Shareholders' equity, Q1 FY2025, at 2025-03-31$7.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001104659-26-096719.Report this figure6.9Shareholders' equity, Q2 FY2025, at 2025-06-30$6.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001104659-26-096719.Report this figure7.3Shareholders' equity, Q3 FY2025, at 2025-09-30$7.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-07, accession 0001104659-25-108169.Report this figure74.9Shareholders' equity, FY2025, at 2025-12-31$74.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001104659-26-096719.Report this figure80.6Shareholders' equity, Q1 FY2026, at 2026-03-31$80.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001104659-26-096719.Report this figure68.4Shareholders' equity, Q2 FY2026, at 2026-06-30$68.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001104659-26-096719.Report this figure

Cash flow

Operating cash flow−$3.6m, Q2 FY2026
Dogwood Therapeutics, Inc., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$k(960)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$960.5k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-08, accession 0001558370-24-014957. Derived: 9-month figure less the 6-month figure.Report this figure(1,469)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$1.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-31, accession 0001558370-25-004167. Derived: 12-month figure less the 9-month figure.Report this figure(937)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$937.4k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-09, accession 0001558370-25-007109.Report this figure(812)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$811.7k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-13, accession 0001558370-25-011319. Derived: 6-month figure less the 3-month figure.Report this figure(910)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$910.1k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-07, accession 0001104659-25-108169. Derived: 9-month figure less the 6-month figure.Report this figure(6,132)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$6.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-18, accession 0001104659-26-031061. Derived: 12-month figure less the 9-month figure.Report this figure(4,683)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$4.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-15, accession 0001104659-26-061938.Report this figure(4,026)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$4.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-14, accession 0001104659-26-096719. Derived: 6-month figure less the 3-month figure.Report this figure(3,273)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$3.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-07, accession 0001104659-25-108169. Derived: 9-month figure less the 6-month figure.Report this figure(3,637)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$3.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-18, accession 0001104659-26-031061. Derived: 12-month figure less the 9-month figure.Report this figure(4,587)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$4.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-15, accession 0001104659-26-061938.Report this figure(3,611)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$3.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-14, accession 0001104659-26-096719. Derived: 6-month figure less the 3-month figure.Report this figure

Shares

Diluted shares (weighted)34.13m, Q2 FY2026
Dogwood Therapeutics, Inc., shares, quarterly
Line itemUnitQ3 FY20222022-09-30Q1 FY20232023-03-31Q1 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares9.2Diluted shares (weighted), Q3 FY2022, three months to 2022-09-309,199,955 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-13, accession 0001558370-23-018708.Report this figure18.3Diluted shares (weighted), Q1 FY2023, three months to 2023-03-3118,330,390 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-10, accession 0001558370-24-007713.Report this figure18.4Diluted shares (weighted), Q1 FY2023, three months to 2023-06-3018,411,399 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-09, accession 0001558370-24-011686.Report this figure0.8Diluted shares (weighted), Q3 FY2023, three months to 2023-09-30763,750 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-08, accession 0001558370-24-014957.Report this figure0.8Diluted shares (weighted), Q1 FY2024, three months to 2024-03-31770,317 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-09, accession 0001558370-25-007109.Report this figure0.9Diluted shares (weighted), Q2 FY2024, three months to 2024-06-30916,031 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-13, accession 0001558370-25-011319.Report this figure1.1Diluted shares (weighted), Q3 FY2024, three months to 2024-09-301,110,317 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-07, accession 0001104659-25-108169.Report this figure1.4Diluted shares (weighted), Q1 FY2025, three months to 2025-03-311,441,535 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-15, accession 0001104659-26-061938.Report this figure1.9Diluted shares (weighted), Q2 FY2025, three months to 2025-06-301,911,128 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-14, accession 0001104659-26-096719.Report this figure1.9Diluted shares (weighted), Q3 FY2025, three months to 2025-09-301,919,433 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-07, accession 0001104659-25-108169.Report this figure33.5Diluted shares (weighted), Q1 FY2026, three months to 2026-03-3133,544,748 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-15, accession 0001104659-26-061938.Report this figure34.1Diluted shares (weighted), Q2 FY2026, three months to 2026-06-3034,129,553 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-14, accession 0001104659-26-096719.Report this figure

Shares outstanding: 33.99mShares outstanding, period not labelled, at 2026-08-1333,992,553 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-14, accession 0001104659-26-096719.Report this figure at Aug 13, 2026, from the cover of the 10-Q filed Aug 14, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. Listed shows no prices and gives no investment advice.